In the TRIUMPH Phase 3 trials, retatrutide is titrated on a slow four-week step-up: 2 mg weekly to start, then 4 mg, then 8 mg, up to a 12 mg weekly maintenance dose, all by subcutaneous injection. Reaching 12 mg takes about 12-16 weeks. The 12 mg arm produced roughly 24% mean body-weight loss at 48 weeks. Retatrutide is investigational and not FDA-approved - these are published trial protocols, not a prescription or a research-peptide dosing guide.
The retatrutide dose schedule at a glance
The published TRIUMPH step-up, all once-weekly subcutaneous, one canonical view:
| Phase | Weekly dose | Duration | Notes |
|---|---|---|---|
| Initiation | 2 mg | ~4 weeks | Standard TRIUMPH start; some clinics use a gentler 0.5-1 mg |
| Step 1 | 4 mg | ~4 weeks | First escalation; GI symptoms concentrate here |
| Step 2 | 8 mg | ~4 weeks | Maintenance in the mid-dose arm |
| Maintenance | 12 mg | ongoing | High-dose arm; ~24% mean weight loss at 48 weeks |
Reaching the 12 mg maintenance dose takes roughly 12-16 weeks from initiation. Retatrutide is investigational and not FDA-approved - this is a trial protocol, not a prescription.
What we read
The Phase 2 retatrutide publication (Jastreboff et al., NEJM 2023); the TRIUMPH-1 through TRIUMPH-4 Phase 3 readouts published through April 2026; the ClinicalTrials.gov protocol details for the TRIUMPH program; and Eli Lilly investor presentations referencing dosing strategy. This is a literature synthesis describing protocols, not a clinical-practice document.
The published dose levels
The TRIUMPH Phase 3 program tests retatrutide across four maintenance doses: 1 mg, 4 mg, 8 mg, and 12 mg, administered weekly via subcutaneous injection. The headline 24% mean body-weight reduction at 48 weeks comes from the 12 mg arm at the highest tested dose.
The dose levels span an unusually wide range for a GLP-1-class compound. Comparators:
| Compound | Maintenance dose range tested in Phase 3 |
|---|---|
| Semaglutide (Wegovy) | 0.25 mg → 2.4 mg weekly |
| Tirzepatide (Zepbound) | 5 mg → 15 mg weekly |
| Retatrutide (TRIUMPH) | 1 mg → 12 mg weekly |
The wider dose range reflects the dose-response characterization goal of the Phase 3 program — Lilly is establishing the curve, not just testing a single approved dose.
The titration schedule
Retatrutide trials use a slower-than-typical dose-titration schedule specifically to manage the GI tolerability profile that all GLP-1-class compounds share.
The published Phase 3 titration approach (paraphrasing the protocols; exact regimens vary by trial arm):
- Initiation — start at 2 mg weekly for ~4 weeks
- Step 1 — increase to 4 mg weekly for ~4 weeks
- Step 2 — increase to 8 mg weekly for ~4 weeks
- Maintenance — at 8 mg or escalate to 12 mg for the high-dose arm
Compare this to tirzepatide SURMOUNT, which titrated 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg in faster increments. Retatrutide's protocol allows longer at each step before escalation, which is a protocol response to the heart-rate signal and GI tolerability.
Why the slower titration
Three reasons documented in the trial design rationale:
1. Glucagon-receptor activation requires adaptation. The third receptor that distinguishes retatrutide from tirzepatide produces energy-expenditure modulation but also a 1–3 bpm heart-rate elevation (see our retatrutide side effects piece). Slower titration lets cardiovascular adaptation track the dose increase rather than spike with it.
2. GI tolerability scales with rate of change, not absolute dose. The published Phase 3 data shows GI side effects concentrating during dose-escalation phases, not at maintenance. Slower titration reduces the per-week rate of change, which reduces peak GI symptoms.
3. The wider dose range needs more dwell time per step. Testing 1 → 12 mg requires more steps than 2.5 → 15 mg. Each step needs adequate dwell time for tolerability data to be meaningful.
Dose-response observations from published data
The Phase 3 readouts surface three structural observations on the dose-response curve:
The 12 mg arm produces the headline 24% weight loss. Lower doses produce proportionally smaller effects — the 4 mg arm in Phase 2 showed roughly 17% weight loss at 48 weeks, the 8 mg arm roughly 22%.
The curve does not plateau as early as GLP-1-only compounds. Even at the 4 mg dose, retatrutide's weight-loss trajectory continues sloping past the 48-week mark in extension data. The mechanistic explanation is the glucagon-receptor energy-expenditure component (see our TRIUMPH-4 results read).
Tolerability scales with titration discipline, not absolute dose. Discontinuation rates due to adverse events at the 12 mg arm are broadly comparable to tirzepatide's 15 mg arm rates from SURMOUNT — which is meaningful given the larger weight-loss effect at the 12 mg retatrutide dose.
What the Phase 3 data does not establish
Three protocol dimensions the published TRIUMPH program does not yet characterize:
Optimal maintenance dose post-target-weight. The trials tested maintenance at the titration endpoint. Whether maintenance can step down to a lower dose post-target — preserving weight loss while reducing side-effect exposure — is not part of the published Phase 3 protocols. This is a typical post-approval study question.
Drug-holiday and tapering protocols. GLP-1-class weight-loss compounds show partial weight regain on discontinuation. Whether tapered discontinuation produces different long-term outcomes than abrupt cessation is not characterized in the published TRIUMPH data.
Combination protocols. Retatrutide is not tested in combination with other GLP-1-class compounds in the published Phase 3 program. Off-label combination is unstudied.
Retatrutide dosing in mL and units
Trial doses are stated in milligrams, but a research context also needs the injection volume, and the two are not interchangeable. The milligram-to-mL conversion depends on how concentrated the vial is after reconstitution:
- A 10 mg vial reconstituted in 1 mL bacteriostatic water is 10 mg/mL, so a 2 mg dose is 0.2 mL = 20 units on a U-100 insulin syringe.
- The same 10 mg vial in 2 mL is 5 mg/mL, so the same 2 mg dose becomes 0.4 mL = 40 units. The dose in milligrams did not change; the volume did.
This is where most dosing errors happen. The full per-vial math for 5 mg, 10 mg, and 20 mg vials is in our retatrutide reconstitution guide, and the peptide calculator does the conversion directly.
Regulatory state — May 2026
Retatrutide is not FDA-approved as of May 2026. Eli Lilly's investor communications through Q1 2026 indicated a 2026 FDA submission target. Standard-review approval would land in 2027; priority-review (less likely) could come in late 2026.
Until approval, retatrutide is not in the legal prescription channel. Compounded retatrutide is not eligible under 503A — see our 503A and PCAC analysis for why the compounding pathway does not extend to non-shortage compounds.
The cleanest legal access route remains trial enrollment where TRIUMPH-5 or successor trials are still recruiting. Outside trial enrollment, no legal medically-supervised retatrutide access channel currently exists.
What this does not tell you
The trial dosing protocols apply to pharma-grade retatrutide administered under medical supervision in a controlled-protocol setting. They do not constitute a recommended dosing schedule for research-peptide retatrutide outside that context.
Research-peptide samples are subject to manufacturing variance, identity-confirmation gaps (the Janoshik analysis documents this for retatrutide specifically), and dose titration without clinical or laboratory oversight. The trial protocols above describe what was tested in the published literature; they are not a research-peptide dosing guide.
Sources
- Jastreboff et al., NEJM 2023 — Phase 2 retatrutide dose-response
- TRIUMPH program: NCT05882045 (TRIUMPH-1), NCT05952713 (TRIUMPH-2), NCT05882187 (TRIUMPH-3), NCT05996731 (TRIUMPH-4)
- SURMOUNT-1 — tirzepatide titration comparator
- Eli Lilly investor relations — TRIUMPH program updates 2025–2026
- Internal: Retatrutide side effects, TRIUMPH-4 results, Retatrutide vs Tirzepatide, 503A and PCAC
Frequently asked
Can I start retatrutide at 2 mg?
In the TRIUMPH Phase 3 trials, 2 mg once weekly was a standard starting dose, held for about four weeks before stepping to 4 mg. Some clinics use a gentler 0.5-1 mg start for tolerability. Retatrutide is investigational and not FDA-approved; this describes trial protocols, not a prescription.
Can you start on 4 mg of retatrutide?
Yes - one TRIUMPH Phase 2 arm initiated at 4 mg weekly rather than 2 mg. The trade-off is more gastrointestinal side effects during escalation, because GI symptoms scale with the rate of dose change rather than the absolute dose. The slower 2 mg start was generally better tolerated. Trial findings, not dosing advice.
Is 1 mg of retatrutide enough?
1 mg was the lowest maintenance dose tested in TRIUMPH and produced roughly 3-5% body-weight reduction - real, but far below the ~24% seen at 12 mg. In the trial data 1 mg reads more as a starting or tolerance step than a target weight-loss dose.
How long is a cycle of retatrutide?
The published TRIUMPH protocols use continuous weekly dosing, not fixed "cycles." Reaching the 12 mg maintenance dose takes about 12-16 weeks of four-week step-ups, and trials dosed to 48 weeks and beyond. Weight regain is common after stopping GLP-1-class drugs, so there is no defined off-cycle in the data.
How many pounds a week do you lose on retatrutide?
Trials report total percentages, not pounds per week. The 12 mg arm reached ~24% mean body-weight loss over 48 weeks - for a 250 lb person that is about 60 lb across roughly 11 months, averaging near 1-1.5 lb/week and front-loaded early. Individual results vary; these are supervised trial outcomes.
How is retatrutide dosed in mL or units?
Dose in mL depends on the vial's concentration after reconstitution. A 10 mg vial in 1 mL of bacteriostatic water is 10 mg/mL, so a 2 mg dose is 0.2 mL, which is 20 units on a U-100 insulin syringe. The full per-vial math is in our [retatrutide reconstitution guide](/articles/retatrutide-reconstitution).
What is the maintenance dose of retatrutide in the trials?
Maintenance in the TRIUMPH high-dose arms was 8 mg or 12 mg weekly. The 12 mg arm produced the ~24% mean body-weight reduction at 48 weeks; the 8 mg arm produced roughly 22% and the 4 mg arm about 17% (Phase 2 data). These are trial figures under medical supervision, not a recommendation.
Is research-grade retatrutide dosed the same as the trial dose?
No. The trial doses describe pharma-grade retatrutide given under medical supervision in a controlled protocol. Research-peptide samples carry manufacturing variance and identity-confirmation gaps - see our [Janoshik 7,164-tests purity analysis](/articles/janoshik-7164-tests-purity-analysis) for retatrutide-specific cross-vendor data. The protocols are not a research-peptide dosing guide.